High ROIC Stocks
CPRX is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
CATALYST PHARMACEUTICALS INC (CPRX) Stock Price & Overview
NASDAQ:CPRX • US14888U1016
Current stock price
24.69 USD
-0.13 (-0.52%)
At close:
24.76 USD
+0.07 (+0.28%)
After Hours:
The current stock price of CPRX is 24.69 USD. Today CPRX is down by -0.52%. In the past month the price increased by 1.52%. In the past year, price increased by 7.02%.
CPRX Key Statistics
52-Week Range19.05 - 26.58
Current CPRX stock price positioned within its 52-week range.
1-Month Range22.16 - 25.43
Current CPRX stock price positioned within its 1-month range.
- Market Cap
- 3.015B
- P/E
- 14.61
- Fwd P/E
- 12.78
- EPS (TTM)
- 1.69
- Dividend Yield
- N/A
CPRX Stock Performance
Today
-0.52%
1 Week
+1.81%
1 Month
+1.52%
3 Months
+6.65%
Longer-term
6 Months +18.47%
1 Year +7.02%
2 Years +64.05%
3 Years +55.09%
5 Years +439.08%
10 Years +3,530.88%
CPRX Stock Chart
CPRX Stock Screens
CPRX currently appears in the following ChartMill screener lists.
High Free Cash Flow Stocks
CPRX is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
Strong Buy Rated Stocks
CPRX is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
High Quality Stocks
CPRX is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
Undervalued Quality Stocks
CPRX appears in our Undervalued Quality Stocks screen, meaning it combines strong fundamentals with an attractive valuation.
CPRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CPRX. When comparing the yearly performance of all stocks, CPRX turns out to be only a medium performer in the overall market: it outperformed 51.7% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to CPRX. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CPRX Earnings
On February 25, 2026 CPRX reported an EPS of 0.41 and a revenue of 152.61M. The company beat EPS expectations (19.63% surprise) and beat revenue expectations (5.34% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.41
Revenue Reported152.613M
EPS Surprise 19.63%
Revenue Surprise 5.34%
CPRX Forecast & Estimates
14 analysts have analysed CPRX and the average price target is 35.02 USD. This implies a price increase of 41.84% is expected in the next year compared to the current price of 24.69.
For the next year, analysts expect an EPS growth of 14.31% and a revenue growth 9.02% for CPRX
Analysts
Analysts88.57
Price Target35.02 (41.84%)
EPS Next Y14.31%
Revenue Next Year9.02%
CPRX Groups
Sector & Classification
CPRX Financial Highlights
Over the last trailing twelve months CPRX reported a non-GAAP Earnings per Share(EPS) of 1.69. The EPS increased by 29.01% compared to the year before.
Income Statements
Revenue(TTM)588.99M
Net Income(TTM)214.33M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 36.39% | ||
| ROA | 19.41% | ||
| ROE | 22.46% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-6.82%
Sales Q2Q%7.61%
EPS 1Y (TTM)29.01%
Revenue 1Y (TTM)19.78%
CPRX Ownership
Ownership
Inst Owners88.61%
Shares122.12M
Float114.57M
Ins Owners5.59%
Short Float %8.47%
Short Ratio8.01
CPRX Latest News, Press Relases and Analysis
15 days ago - By: Chartmill
CPRX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CPRX
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 182 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Company Info
IPO: 2006-11-08
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134 US
CEO: Patrick J. McEnany
Employees: 182
Phone: 13055292522
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What does CATALYST PHARMACEUTICALS INC do?
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 182 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Can you provide the latest stock price for CATALYST PHARMACEUTICALS INC?
The current stock price of CPRX is 24.69 USD. The price decreased by -0.52% in the last trading session.
Does CPRX stock pay dividends?
CPRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CPRX stock?
CPRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is CPRX stock listed?
CPRX stock is listed on the Nasdaq exchange.
What is the expected growth for CPRX stock?
The Revenue of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 9.02% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a market capitalization of 3.02B USD. This makes CPRX a Mid Cap stock.